HMGB3P17

Across TCGA pan-cancer cohorts, HMGB3P17 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of HMGB3P17’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where HMGB3P17 RNA is repressed in tumor relative to normal tissue. In most cancer types HMGB3P17 is over-expressed in tumor, although a few such as BRCA and THCA show the opposite, repressed pattern.

BRCA, KIRC, and THCA are the cancer types where HMGB3P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HMGB3P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.074	.024	4	view →
KIRC	Male	All	+0.044	.014	2	view →
THCA	Female	All	−0.021	.007	2	view →
KIRP	All	All	+0.021	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

HMGB3P17–BRCA

Open the BRCA breakdown →